期刊文献+

磷霉素氨丁三醇治疗神经外科术后常见呼吸道及尿路感染的效果观察 被引量:4

下载PDF
导出
摘要 目的探究磷霉素氨丁三醇治疗神经外科术后常见呼吸道及尿路感染的临床疗效。方法选取2012年1月至2013年1月唐河县人民医院神经外科术后发生呼吸道感染和尿路感染的住院患者86例,根据病情分为3组,即单发呼吸道感染组、单发尿路感染组、合并感染组,对所有患者使用磷霉素氨丁三醇进行抗感染治疗,观察其临床效果及药物安全性。结果磷霉素氨丁三醇治疗单发呼吸道感染和单发尿路感染的有效率明显高于呼吸道感染合并尿路感染,差异具有统计学意义(P<0.05);药敏试验结果显示致病菌对磷霉素氨丁三醇敏感率达90.20%;合计有4例患者发生药物不良反应,发生率仅为5.00%。结论磷霉素氨丁三醇针对单发感染如呼吸道感染、尿路感染具有较强的抗感染能力,对于多重合并感染则有一定的局限,需结合患者自身情况及病情特点合理选择与应用。
作者 王永哲
出处 《河南医学研究》 CAS 2015年第4期95-96,共2页 Henan Medical Research
  • 相关文献

参考文献6

二级参考文献21

  • 1王明贵.喹诺酮类抗菌药的耐药性及质粒介导耐药机制[J].中华医学杂志,2006,86(9):645-647. 被引量:35
  • 2胡辉,张永信.磷霉素氨丁三醇的临床评价[J].世界临床药物,2007,28(2):79-82. 被引量:9
  • 3Schito GC.Why fosfomycin trometamol as first line thera-py for uncomplicated UTI[J]?IntJAntimicrob Agents,2003,22(Suppl 2):S79-S83.
  • 4Galatti L,Sessa A,Mazzaglia G,et al.Antibiotic pre-scribing for acute and recurrent cystitis in primary care[J].JAntimicrob Chemother,2006,57(3):551-556.
  • 5Naber KG,Bergman B,Bishop MC,et al.EAU guide-lines for the management of urinary and male genital tractinfections[J].Eur Urol,2001,40(5):576-588.
  • 6Minassian MA.Williams JD.The clinical pharmacolo-gy of fosfomycin trometamol[J].Rev Contemp Phar-macother,1995,6(2):45.
  • 7Naber KO,Fosfomycin Trometamol in treatment ofuncomplicatated Lower urinary tract infections inadultwomen-an overview[J].In-Fection,1992,20(suppl.4):310-314.
  • 8Mao Gowan A P,Infection,1990年,18卷,增2期,S107页
  • 9Schito GC. Why fosfomycintrometamol as first line therapy for uncomplicated UTI9 [J]. Int J Antimicrob Agents, 2003, 22(Suppl 2) : 79-83.
  • 10Falagas ME, Vouloumanou EK, Togias AG, et al cin versus other antibiotics for the treammnt of meta analysis of randomized controlled trials[J]. crob Chemother,2010,65(9) : 1862 -1877.

共引文献13

同被引文献30

  • 1KEATING G M. Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria[J]. Drugs, 2013, 73(17): 1951-1966.
  • 2HOPKINS L, MCCROSKEY D, REEVES G, et al. Implementing a urinary tract infection clinical practice guideline in an ambulatory urgent care practice[J]. Nurse Pract, 2014, 39(4): 50-54.
  • 3CLSI.CLSI-M100-S23[DB/OL].(2014-08-07) [2015-07-12]. http://www.clinphar.cn/thread-231795-1-1.html.
  • 4PAPAGEORGIOU El. Fuzzy cognitive map software tool for treatment management of uncomplicated urinary tract infection[J]. Comput Methods Programs Biomed, 2012, 105(3):233-245.
  • 5WILSON DT,MAY DB. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum 13-1actamase- producing Escherichia coli[J]. Am J Ther,2013,20(6): 685- 690.
  • 6PEREZ F,VAN DUIN D. Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients[J]. Cleve Clin J Med,2013,80(4): 225.
  • 7REFFERT JL, SMITH WJ. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists[J]. Pharmacotherapy, 2014, 34(8):845-857.
  • 8郑波,吕嫒.磷霉素氨丁三醇治疗尿路感染研究进展[C].//第8届全国抗菌药物临床药理学术会议论文集,2010:311-314.
  • 9KAYE KS, POGUE JM. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management[J]. Pharmacotherapy, 2015, 35(10):949-962.
  • 10GREEN D A,SRINIVAS N,WATZ N,et al. A Pediatric Case of New Delhi Metallo-β-Lactamase-l-Producing Enterobaeteriaceae in The United States[J]. The Pediatric infectious disease journal,2013,32(11): 1291-1294.

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部